Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2019-07-29 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Opthea European Patent Application to be Granted 3 pages 73.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 30 July 2019 from Opthea Limited announcing that the European Patent Office has issued a Notice of Intention to Grant a patent application covering their product OPT-302. The content focuses on intellectual property updates, clinical trial status, and business strategy related to patent protection. There are no financial statements, earnings data, management discussion of financial results, or regulatory certifications. The document is a corporate announcement about patent grant status and business implications, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report. The document fits best into the category of a general regulatory announcement or compliance-related disclosure that does not fit other specific categories, which corresponds to Regulatory Filings (RNS).
2019-07-29 English
Opthea Provides Timing Update on OPT-302 Clinical Trials 3 pages 69.6KB
Capital/Financing Update Classification · 90% confidence The document is an ASX and media release dated 22 July 2019 from Opthea Limited, providing an update on the timing of primary data reporting from ongoing Phase 2b and Phase 2a clinical trials for OPT-302 in wet AMD and diabetic macular edema. It includes forward-looking statements, clinical trial identifiers, and details about the drug and disease background. The document is a public announcement about clinical trial progress and timing updates, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial analysis. It is a corporate announcement related to clinical development progress and timing updates, which fits best under Capital/Financing Update (CAP) as it relates to clinical trial progress impacting company valuation and financing prospects. The document length is 9538 characters, sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2019-07-21 English
Change in substantial holding 2 pages 342.4KB
Regulatory Filings
2019-06-03 English
Opthea Completes Final Patient Visit in Phase 2b wAMD Trial 3 pages 116.9KB
Capital/Financing Update Classification · 90% confidence The document is an ASX and media release dated 15 May 2019 from Opthea Limited announcing the completion of the final patient visit in their Phase 2b clinical trial for a drug candidate (OPT-302) for wet age-related macular degeneration (AMD). The content focuses on clinical trial progress, patient enrollment, and the expected timeline for top-line results. It includes background on the drug, disease, company, and investment risks. There are no financial statements, earnings data, or regulatory filings referenced. The document is a corporate announcement about clinical trial progress and upcoming data release, typical of a capital/financing update or clinical development update. It is not a full financial report, earnings release, or regulatory filing. Given the nature of the announcement about clinical trial milestones and upcoming data, the best fitting category is Capital/Financing Update (CAP).
2019-05-14 English
Appendix 3B 12 pages 179.7KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. It details the class and number of securities issued, terms, issue price, purpose, and compliance with ASX rules, including placement capacity calculations under rules 7.1 and 7.1A. The content focuses on capital raising activities and securities issuance rather than financial results, management changes, or other report types. Therefore, this document is best classified as a Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement of a report but a substantive filing about capital changes.
2019-04-11 English
Change of Director's Interest Notice - MB 4 pages 165.2KB
Director's Dealing Classification · 100% confidence The document is a notification regarding a director's personal share transactions, specifically the sale of shares by Dr. Megan Baldwin, the CEO and Managing Director of Opthea Limited. It includes detailed information about the number of shares sold, the price, and the resulting shareholding. The document references Appendix 3Y, which is a standard form used for reporting changes in directors' interests in securities to the ASX. There is no financial report, earnings data, or management discussion present. The content fits the definition of a Director's Dealing report, which is a report of personal share transactions by company directors and executives (insider trades).
2019-04-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.